Overview

Study of EBI-005 in Dry Eye Disease (DED)

Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double masked study designed to evaluate the safety of EBI-005 5 mg/mL topical ophthalmic solution given three times daily (TID) compared to vehicle-control over a one year period in subjects with dry eye disease (DED). Approximately 188 subjects will be enrolled to either EBI-005 or vehicle at up to 15 centers in the United States (US) and Canada.
Phase:
Phase 3
Details
Lead Sponsor:
Eleven Biotherapeutics